Systemic treatment of sarcoidosis

Ocular Immunology and Inflammation

Volumn 19, Issue 2, 2011, Pages 145-150

  Murray, Philip I ^a,d   Bodaghi, Bahram ^b   Sharma, Om P ^c  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d CITY HOSPITAL   (United Kingdom)

Author keywords

extraocular; intraocular; RCT; sarcoidosis; treatment

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BUDESONIDE; CALCIUM; CHLORAMBUCIL; CHLOROQUINE; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID; OXYPHENBUTAZONE; PENTOXIFYLLINE; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VITAMIN D;

ARTICLE; ASPERGILLOMA; BRONCHIECTASIS; COUGHING; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; EXTRAOCULAR SARCOIDOSIS; FORCED VITAL CAPACITY; HEMOPTYSIS; HUMAN; INTRAOCULAR SARCOIDOSIS; LUNG ALVEOLITIS; LUNG FUNCTION TEST; LUNG SARCOIDOSIS; OSTEOPOROSIS; SARCOIDOSIS;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ADRENAL CORTEX HORMONES; DRUG ADMINISTRATION SCHEDULE; EVIDENCE-BASED MEDICINE; EYE DISEASES; GLUCOCORTICOIDS; HUMANS; IMMUNOGLOBULIN G; META-ANALYSIS AS TOPIC; OXYPHENBUTAZONE; PREDNISOLONE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, TUMOR NECROSIS FACTOR; SARCOIDOSIS; SARCOIDOSIS, PULMONARY;

EID: 79953101586     PISSN: 09273948     EISSN: 17445078     Source Type: Journal    
DOI: 10.3109/09273948.2010.542870     Document Type: Article

References (46)

1. James DG, Carstairs LS, Trowell J, Sharma OP. Treatment of sarcoidosis: report of a controlled therapeutic trial. Lancet. 1967;2:526-528.
2. Selroos O, Sellergren TL. Corticosteroid therapy of pul-monary sarcoidosis: a prospective evaluation of alternate day and daily dosage in stage II disease. Scand J Respir Dis. 1979;60:215-221. (Pubitemid 10193545)
3. Kropp R, Goebel D, Matthiessen W, et al. Comparison of 3 times weekly versus daily corticosteroid administration in sarcoidosis: a prospective, randomized multicenter study of the Scientifc Society for the Therapy of Lung Diseases. Prax Klin Pneumol. 1986;40:123-128.
4. Rizzato G, Riboldi A, Imbimbo B, Torresin A, Milani S. The long-term effcacy and safety of two different corticosteroids in chronic sarcoidosis. Respir Med. 1997;91:449-460. (Pubitemid 27359136)
5. Zych D, Pawlicka L, Zieli?ski J. Comparison of the effec-tiveness of budesonide and prednisone in the maintenance treatment of pulmonary sarcoidosis. Pol Arch Med Wewn. 1992;88:30-37.
6. Pietinalho A, Tukiainen P, Haahtela T, Persson T, Selroos O. Oral prednisolone followed by inhaled budesonide in newly diagnosed pulmonary sarcoidosis: a double-blind, placebo-controlled multicenter study Finnish Pulmonary Sarcoidosis Study Group. Chest. 1999;116:424-431. (Pubitemid 29382128)
7. Pietinalho A, Tukiainen P, Haahtela T, Persson T, Selroos O; Finnish Pulmonary Sarcoidosis Study Group. Early treatment of stage II sarcoidosis improves 5-year pulmonary function. Chest. 2002;121:24-31. (Pubitemid 34114224)
8. Zych D, Pawlicka L, Zielinski J. Inhaled budesonide vs pred-nisone in the maintenance treatment of pulmonary sarcoido-sis. Sarcoidosis. 1993;10:56-61. (Pubitemid 23140876)
9. Milman N, Graudal N, Grode G, Munch E. No effect of high-dose inhaled steroids in pulmonary sarcoidosis: a double-blind, placebo-controlled study J Intern Med. 1994;236:285-290. (Pubitemid 24283067)
10. Alberts C, van der Mark TW, Jansen HM. Inhaled budesonide in pulmonary sarcoidosis: a double-blind, placebo-controlled study Dutch Study Group on Pulmonary Sarcoidosis. Eur Respir J. 1995;8:682-688.
11. du Bois RM, Greenhalgh PM, Southcott AM, Johnson NM, Harris TA. Randomized trial of inhaled futicasone propi-onate in chronic stable pulmonary sarcoidosis: a pilot study Eur Respir J. 1999;13:1345-1350. (Pubitemid 29357151)
12. Rossman MD, Newman LS, Baughman RP, et al. A double-blinded, randomized, placebo-controlled trial of infiximab in subjects with active pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2006;23:201-208. (Pubitemid 47596315)
13. Baughman RP, Drent M, Kavuru M, et al. Sarcoidosis Investigators. Infiximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med. 2006;174:795-802. (Pubitemid 44511661)
14. Judson MA, Baughman RP, Costabel U, et al. Centocor T48 Sarcoidosis Investigators. Effcacy of infiximab in extrapul-monary sarcoidosis: results from a randomised trial. Eur Respir J. 2008;31:1189-1196.
15. Stern BJ, Schonfeld SA, Sewell C, Krumholz A, Scott P, Belendiuk G. The treatment of neurosarcoidosis with cyclosporine. Arch Neurol. 1992;49:1065-1072.
16. Wyser CP, van Schalkwyk EM, Alheit B, Bardin PG, Joubert JR. Treatment of progressive pulmonary sarcoidosis with cyclosporin A: a randomized controlled trial. Am J Respir Crit Care Med. 1997;156:1371-1376. (Pubitemid 27505496)
17. Baughman RP, Winget DB, Lower EE. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis Vasc Diffuse Lung Dis. 2000;17:60-66. (Pubitemid 30157757)
18. Baltzan M, Mehta S, Kirkham TH, Cosio MG. Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis. Am J Respir Crit Care Med. 1999;160:192-197 (Pubitemid 29326087)
19. Park MK, Fontana JR, Babaali H, et al. Steroid-sparing effects of pentoxifylline in pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2009;26:121-131.
20. Reich JM. Adverse long-term effect of corticosteroid therapy in recent-onset sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2003;20:227-34. (Pubitemid 37351545)
21. Paramothayan NS, Lasserson TJ, Jones PW. Corticosteroids for pulmonary sarcoidosis. Cochrane Database Syst Rev. 2005;:CD001114.
22. Schutt AC, Bullington WM, Judson MA. Pharmacotherapy for pulmonary sarcoidosis: a Delphi consensus study Respir Med. 2010;104:717-723.
23. King CS, Kelly W. Treatment of sarcoidosis. Dis Mon. 2009;55:704-718.
24. Baughman RP, Costabel U, du Bois RM. Treatment of sarcoidosis. Clin Chest Med. 2008;29:533-548, ix-x. (Pubitemid 351784486)
25. Israel HL, Sones M, Harrell D. Cortisone treatment of sarcoidosis: experience with thirty-six cases. J Am Med Assoc 1954;156:461-466.
26. Gupta SK. Treatment of sarcoidosis patients by steroid aerosol: a ten-year prospective study from eastern India. Sarcoidosis. 1989;6:51-54. (Pubitemid 19109686)
27. Pietinalho A, Tukiainen P, Haahtela T, Persson T, Selroos O. Early treatment of stage II sarcoidosis improves 5-year pulmonary function. Chest. 2002;121:24-31. (Pubitemid 34114224)
28. Baughman RP, Lower EE. Alternatives to corticosteroids in the treatment of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 1997;14:121-130 (Pubitemid 27427344)
29. Pacheco Y, Marechal C, Marechal F, Biot N, Perrin Fayolle M. Azathioprine treatment of chronic pulmonary sarcoidosis. Sarcoidosis. 1985;2:107-113. (Pubitemid 16257982)
30. Kataria YP. Chlorambucil in sarcoidosis. Chest. 1980;78:36-43. (Pubitemid 10090322)
31. Gibson GJ. Sarcoidosis: old and new treatments. Thorax. 2001;56:336-339. (Pubitemid 32398120)
32. Siltzbach LE, Teirstein AS. Chloroquine therapy in 43 patients with intrathoracic and cutaneous sarcoidosis. Acta Med Scand Suppl. 1964;425:302-308.
33. Sharma OP Effectiveness of chloroquine and hydroxychloroquine in treating selected patients with sarcoidosis with neurological involvement Arch Neurol 1998; 55: 1248-1254. (Pubitemid 28427497)
34. Field S, Regan AO, Sheahan K, Collins P. Recalcitrant cutaneous sarcoidosis responding to adalimumab but not to etanercept. Clin Exp Dermatol. 2010;35:795-796.
35. Patel SR. Systemic sarcoidosis with bone marrow involvement responding to therapy with adalimumab: a case report. J Med Case Rep. 2009;3:8573.
36. Massara A, Cavazzini L, La Corte R, Trotta F Sarcoidosis appearing during anti-tumor necrosis factor alpha therapy: a new "class effect" paradoxical phenomenon. Two case reports and literature review. Semin Arthritis Rheum. 2010;39:313-319.
37. Gibson GJ, Prescott RJ, Muers MF, et al. British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment. Thorax. 1996;51:238-247.
38. Baughman RP, Lower EE, Bradley DA, Raymond LA, Kaufman A. Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial. Chest. 2005;128:1062-1047.
39. Rothova A. Ocular involvement in sarcoidosis. Br J Ophthalmol. 2000;84:110-116. (Pubitemid 30251644)
40. Edelsten C, Pearson A, Joynes E, Stanford MR, Graham EM. The ocular and systemic prognosis of patients presenting with sarcoid uveitis. Eye (Lond). 1999;13:748-753. (Pubitemid 30050502)
41. Dev S, McCallum RM, Jaffe GJ. Methotrexate treatment for sarcoid-associated panuveitis. Ophthalmology. 1999;106:111-118.
42. Bhat P, Cervantes-Castañeda RA, Doctor PP, Anzaar F, Foster CS. Mycophenolate mofetil therapy for sarcoidosis-associated uveitis. Ocul Immunol Infamm. 2009;17:185-190.
43. Dios Castro E, Herreras Cantalapiedra JM, Calonge Cano M, Osés S. Ocular sarcoidosis: retrospective study of 18 cases. Arch Soc Esp Oftalmol. 2002;77:301-308.
44. Petropoulos IK, Vaudaux JD, Guex-Crosier Y Anti-TNF-alpha therapy in patients with chronic non-infectious uveitis: the experience of Jules Gonin Eye Hospital. Klin Monbl Augenheilkd. 2008;225:457-461. (Pubitemid 352016484)
45. Murray PI. Idiopathic (autoimmune) sight-threatening uveitis. In: Wormald R, Smeeth L, Henshaw K, eds. Evidence-Based Ophthalmology. London: BMJ Books;2004: 167-173.
46. Doycheva D, Deuter C, Stuebiger N, Zierhut M. Interferonalpha-associated presumed ocular sarcoidosis. Graefes Arch Clin Exp Ophthalmol. 2009;247:675-680.